Bristol Myers Squibb Co (BMY) stock
BMYNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as CELG.RI
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 14/3030% below fair value
$61.35−1.58 (-2.51%)
Close on Nov 17, 2026Market cap $125.41BP/E 13.6Yield 4.06%
Bristol Myers Squibb operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Bristol Myers Squibb's operating cash flow for the twelve months ending Sep 30, 2026 was $10.65B, down 35.9% year over year. For fiscal 2025 it was $14.16B, down 6.8% from the year before. Over ten years it grew 21.0% a year on average. The highest annual figure on record is $16.21B in fiscal 2021.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.16B | -6.8% |
| FY2024 | Dec 31, 2024 | $15.19B | +9.6% |
| FY2023 | Dec 31, 2023 | $13.86B | +6.1% |
| FY2022 | Dec 31, 2022 | $13.07B | -19.4% |
| FY2021 | Dec 31, 2021 | $16.21B | +15.3% |
| FY2020 | Dec 31, 2020 | $14.05B | +71.2% |
| FY2019 | Dec 31, 2019 | $8.21B | +16.2% |
| FY2018 | Dec 31, 2018 | $7.07B | +34.0% |
| FY2017 | Dec 31, 2017 | $5.28B | +72.5% |
| FY2016 | Dec 31, 2016 | $3.06B | +45.3% |
| FY2015 | Dec 31, 2015 | $2.11B | -33.1% |
| FY2014 | Dec 31, 2014 | $3.15B | -11.2% |
| FY2013 | Dec 31, 2013 | $3.55B | -48.9% |
| FY2012 | Dec 31, 2012 | $6.94B | +43.4% |
| FY2011 | Dec 31, 2011 | $4.84B | +7.8% |
| FY2010 | Dec 31, 2010 | $4.49B | +10.5% |
| FY2009 | Dec 31, 2009 | $4.07B | +9.7% |
| FY2008 | Dec 31, 2008 | $3.71B | +17.6% |
| FY2007 | Dec 31, 2007 | $3.15B | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $4.18B | -33.8% |
| Q2 FY2026 | Jun 30, 2026 | $3.39B | -13.4% |
| Q1 FY2026 | Mar 31, 2026 | $1.10B | -43.5% |
| Q4 FY2025 | Dec 31, 2025 | $1.97B | -55.5% |
| Q3 FY2025 | Sep 30, 2025 | $6.31B | +12.9% |
| Q2 FY2025 | Jun 30, 2025 | $3.92B | +68.4% |
| Q1 FY2025 | Mar 31, 2025 | $1.95B | -31.1% |
| Q4 FY2024 | Dec 31, 2024 | $4.44B | +4.4% |
| Q3 FY2024 | Sep 30, 2024 | $5.59B | +17.7% |
| Q2 FY2024 | Jun 30, 2024 | $2.33B | +23.3% |
| Q1 FY2024 | Mar 31, 2024 | $2.83B | -4.6% |
| Q4 FY2023 | Dec 31, 2023 | $4.25B | +28.6% |
| Q3 FY2023 | Sep 30, 2023 | $4.75B | +28.9% |
| Q2 FY2023 | Jun 30, 2023 | $1.89B | -16.5% |
| Q1 FY2023 | Mar 31, 2023 | $2.97B | -22.1% |
| Q4 FY2022 | Dec 31, 2022 | $3.31B | -18.5% |
| Q3 FY2022 | Sep 30, 2022 | $3.69B | -30.0% |
| Q2 FY2022 | Jun 30, 2022 | $2.26B | -26.1% |
| Q1 FY2022 | Mar 31, 2022 | $3.81B | -0.3% |
| Q4 FY2021 | Dec 31, 2021 | $4.06B | +20.9% |
| Q3 FY2021 | Sep 30, 2021 | $5.27B | +132.3% |
| Q2 FY2021 | Jun 30, 2021 | $3.06B | -31.9% |
| Q1 FY2021 | Mar 31, 2021 | $3.82B | -2.9% |
| Q4 FY2020 | Dec 31, 2020 | $3.36B | +53.8% |
| Q3 FY2020 | Sep 30, 2020 | $2.27B | -11.3% |
| Q2 FY2020 | Jun 30, 2020 | $4.49B | +115.7% |
| Q1 FY2020 | Mar 31, 2020 | $3.94B | +183.2% |
| Q4 FY2019 | Dec 31, 2019 | $2.18B | -38.6% |
| Q3 FY2019 | Sep 30, 2019 | $2.56B | +99.8% |
| Q2 FY2019 | Jun 30, 2019 | $2.08B | +97.1% |
| Q1 FY2019 | Mar 31, 2019 | $1.39B | +18.3% |
| Q4 FY2018 | Dec 31, 2018 | $3.56B | +218.3% |
| Q3 FY2018 | Sep 30, 2018 | $1.28B | -25.3% |
| Q2 FY2018 | Jun 30, 2018 | $1.06B | -33.3% |
| Q1 FY2018 | Mar 31, 2018 | $1.18B | +36.5% |
| Q4 FY2017 | Dec 31, 2017 | $1.12B | -22.6% |
| Q3 FY2017 | Sep 30, 2017 | $1.71B | – |
| Q2 FY2017 | Jun 30, 2017 | $1.58B | – |
| Q1 FY2017 | Mar 31, 2017 | $861.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.44B | – |
See a number that looks wrong?